Compare RPC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RPC | SPRY |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | 267 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 932.7M | 823.2M |
| IPO Year | N/A | 2020 |
| Metric | RPC | SPRY |
|---|---|---|
| Price | $8.74 | $8.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $11.00 | ★ $40.00 |
| AVG Volume (30 Days) | 510.2K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $16.82 | $87.40 |
| Revenue Next Year | $15.80 | $81.64 |
| P/E Ratio | $53.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.79 | $6.66 |
| 52 Week High | $9.32 | $18.63 |
| Indicator | RPC | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 70.48 | 53.70 |
| Support Level | $6.94 | $8.61 |
| Resistance Level | N/A | $9.46 |
| Average True Range (ATR) | 0.32 | 0.49 |
| MACD | 0.09 | 0.11 |
| Stochastic Oscillator | 89.78 | 53.39 |
Ridgepost Capital Inc, formelrly P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.